摘要
EGFR基因突变与肺癌发生发展密切相关,介绍不同EGFR基因突变类型对靶向药物TKI的敏感性以及回顾靶向药物耐药机制的研究进展,进一步指导临床靶向用药.
EGFR mutations are closely associated with lung cancer development,this paper introduces the effectiveness of tyrosine kinase inhibitors on different epidermal growth factor receptor mutations and reviews the research progress of targeted drug resistance mechanisms,the aimis to further guide clinical targeted drugs.
作者
钱璐
边莉
QIAN Lu;BIAN Li(Dept.of Pathology,The 1st Affliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)
出处
《昆明医科大学学报》
CAS
2017年第8期126-129,共4页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(81460355)
关键词
表皮生长因子受体
非小细胞肺癌
酪氨酸激酶抑制剂
Epidermal growth factor receptor
Non-small cell lung cancer
Tyrosine kinase inhibitors